We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Safety Concerns Lead EMA Panel To Nix Kynamro and Fanapt
Safety Concerns Lead EMA Panel To Nix Kynamro and Fanapt
January 16, 2013
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against approval of Genzyme and Isis Pharmaceuticals’ familial hypercholesterolemia drug Kynamro and Vanda Pharmaceuticals’ schizophrenia treatment Fanapt, citing safety issues with both.